-+ 0.00%
-+ 0.00%
-+ 0.00%

The Zhitong Finance App learned that on August 17, AstraZeneca (AZN.US) and Daiichi Sankyo jointly announced that the Phase III Destiny-Lung04 study of Enhertu (tetrastuzumab) single-agent first-line treatment of non-small cell lung cancer (NSCLC) had achieved a high level of positive results.

Zhitongcaijing·08/17/2026 12:49:07
Listen to the news
The Zhitong Finance App learned that on August 17, AstraZeneca (AZN.US) and Daiichi Sankyo jointly announced that the Phase III Destiny-Lung04 study of Enhertu (tetrastuzumab) single-agent first-line treatment of non-small cell lung cancer (NSCLC) had achieved a high level of positive results.